TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) announces that, effective today, Raymond D. Harari, a director of LabGold, has been appointed as President of the Company, and that Robert Mason has been appointed as Corporate Secretary.

“I am delighted to welcome Ray as President and Rob as Corporate Secretary of LabGold,” said Roger Moss, Chief Executive Officer of LabGold. “Since joining the Board of Directors in mid-October, Ray has already made an immense contribution to the Company, bringing a fresh perspective, tremendous energy and a wealth of capital markets experience. His impact has been immediate, and I am confident that his expanded leadership role will be instrumental as we evaluate strategic opportunities and position LabGold for its next phase of growth. Rob’s extensive experience in securities law, corporate governance and mining transactions further strengthens our team at an important time for the Company. I look forward to working closely with both Ray and Rob as we pursue our shared objective of maximizing shareholder value.”

Mr. Harari is the founder of Canalis Capital, a Panama-based merchant banking firm focused on the natural resources sector. He has extensive experience in corporate finance, capital markets and strategic transactions, having held senior executive and board positions with numerous publicly traded mineral exploration companies throughout his career.

Mr. Mason is the founder and principal of Mason Law, a Toronto-based law firm specializing in corporate and securities law, mergers and acquisitions, and mining transactions. Mr. Mason has over 25 years of experience advising publicly traded companies, institutional investors and boards of directors on corporate finance, capital markets transactions, strategic acquisitions and corporate governance matters.

To create vacancies for the appointments of Messrs. Harari and Mason, Dr. Roger Moss has resigned as President, remaining as the Company’s Chief Executive Officer and director, and Mr. Bill Johnstone has resigned as corporate secretary. The Company thanks Mr. Johnstone for his six plus years of service to LabGold.

About Labrador Gold

Labrador Gold is a Canadian-based hybrid mining and investment issuer focused on the acquisition and exploration of prospective mineral projects in Canada and on strategic investments in mining companies and assets that the Company believes have the potential to generate long-term value.

The Mariposa project covers 16,000 ha in the White Gold District and is 40 kilometres southeast of the White Gold Project and 30 kilometres east-northeast of Fuerte’s Coffee gold project. Mariposa shares many geological similarities to both the Golden Saddle (part of the White Gold Project) and Coffee gold deposits including host lithologies, mineralization style and structural control. The property occurs at the headwaters of significant placer gold producing creeks with historic placer production of 73,000 oz from Scroggie Creek (3) indicative of significant bedrock gold mineralization yet to be fully defined. Six significant gold occurrences have been delineated by over 13,000 soil samples to date, including the most advanced Skookum Main and Skookum West prospects. LabGold has the option to earn a 100% interest in the Mariposa project from Pacific Ridge Exploration Ltd.

The Watson Project, a 70:30 joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, copper and zinc). The proposed road to the Ring of Fire, expected to begin construction in mid-2026, runs through the Watson property and, once complete, will significantly reduce exploration and development costs.

The 100% owned Hopedale property covers much of the Archean-age Florence Lake greenstone belt, which extends over 60 kilometers. While typical of greenstone belts globally, the area has been underexplored. LabGold’s work to date has identified gold anomalies in rocks, soils, and lake sediments across a three-kilometer section of the northern portion of the belt. Five gold occurrences lie along this trend, four of which were discovered by LabGold. Additional anomalous gold values occur across approximately 40 kilometers of the southern portion of the belt. Recent exploration has also demonstrated potential for copper, nickel, and cobalt.

The 100% owned Borden Lake project near Chapleau, Ontario lies immediately southeast of Discovery Silver Corp’s Borden gold mine. Past exploration by LabGold identified two anomalous gold zones based on geochemistry and geophysics.

The Company has 286,012,288 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol LAB.

For more information, please contact:

Roger Moss, CEO and Director
Tel: 416-704-8291
Email: rmoss@labradorgold.com

Website: www.labradorgold.com
X: @LabGoldCorp

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking information is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. Any such forward-looking information is based on information currently available to LabGold and is based on assumptions and analyses made in light of LabGold’s experience and perception of historical trends and current conditions. While the Company considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. Readers are cautioned that actual results may vary from the forward-looking information, and undue reliance should not be placed on such forward-looking information.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Additional risk factors can also be found in LabGold’s financial statements and management’s discussion and analysis, which are available under LabGold’s profile on SEDAR+ at www.sedarplus.ca.

Unless otherwise indicated, the forward-looking statements in this news release are based on the Company’s expectations at the date of this news release. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. LabGold undertakes no obligation to update or revise such forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise, except as required by applicable law.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in three upcoming investor conferences:

  • 3rd Annual Guggenheim Healthcare Innovation Conference; fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. ET
  • 2026 Jefferies Global Healthcare Conference in London; presentation on Tuesday, November 17, 2026, at 10:30 a.m. ET / 3:30 p.m. GMT
  • 9th Annual Evercore Healthcare Conference; fireside chat on Tuesday, December 1, 2026, at 9:35 a.m. ET

Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.

IR/Corporate Contact:
Argot Partners
maze@argotpartners.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

Seyond at SCEWC26

Combining comprehensive LiDAR sensing, agentic AI-powered analytics, and technology collaborations to advance smart cities, critical infrastructure and safe spaces.

SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Seyond, a global provider of high-performance LiDAR solutions, is expanding its smart city and smart spaces solutions through advanced 3D sensing and technology collaborations. By connecting spatial data with agentic AI-powered analytics and computing platforms, Seyond helps organizations improve safety, transportation, and infrastructure operations.

Growing Demand for Smart Cities and Intelligent Infrastructure

Smart cities are becoming an operational priority as organizations seek real-time intelligence to improve safety, transportation and operational efficiency. According to LP Information, the global smart-city LiDAR market was valued at approximately $358 million in 2025, with a projected compound annual growth rate of 18.7%, suggesting a market of approximately $425 million in 2026.

Demand for spatial intelligence now extends beyond roadways to airports, stadiums, utilities, data centers, and other critical infrastructures. These applications create opportunities to better understand movement, optimize space utilization, and improve operations.

Based on industry research and internal assumptions, Seyond estimates an illustrative annual serviceable addressable market of $1.3 billion to $2.0 billion in 2026 for expanded stationary LiDAR applications outside China. This sensor-focused estimate represents potential market opportunity, not projected company revenue.

Seyond: Enabling Spatial Intelligence Across Smart Environments

Seyond’s comprehensive LiDAR portfolio, spanning ultra-long-range to short-range sensing, supports applications from transportation infrastructure to localized indoor and outdoor environments. Its technology generates high-resolution 3D spatial data to measure vehicle movement, pedestrian flows, and environmental activity without relying on identifiable photographic imagery, providing a privacy-conscious foundation for spatial analytics.

These capabilities support continuous spatial awareness across intersections, transportation hubs, commercial facilities, and public gathering spaces. Combined with AI-powered analytics and computing platforms, Seyond’s sensing technology helps organizations translate physical-world data into actionable insights, enabling more responsive infrastructure and better-informed operational decisions.

Expanding Technology Collaborations to Deliver Complete Operational Twin Solutions

Delivering practical smart city solutions increasingly requires collaboration across sensing, computing, AI, and software. One example is the digital operational twins, dynamic digital representation of a physical environment that reflects activity and movement in real time, helping operators understand changing conditions and make informed decisions.

At Smart City Expo World Congress 2026, November 3–5 in Barcelona, Seyond will participate as an exhibition partner at the Dell Technologies booth, showcasing a live LiDAR-powered operational twin.

By combining Seyond’s sensing capabilities with technologies from Dell and NVIDIA, the demonstration will illustrate how integrated solutions can support pedestrian-flow analysis, space utilization, and real-time operational awareness. The solution will feature a Dell Technologies system powered by the NVIDIA DGX Spark, which combines a 20-core Arm Grace CPU with an NVIDIA Blackwell GPU. Fused data from LiDAR, video, and other sensors feeds a live operational twin, giving operators a unified view of activity across the environment. The solution integrates vision AI agents built with NVIDIA Metropolis Blueprint for video search and summarization (VSS) and NVIDIA Cosmos to enhance scene understanding and support informed operational decisions.

Seyond is also collaborating with AMSYS to advance integrated spatial intelligence solutions for large-scale venues and public environments. Combining Seyond’s LiDAR sensing with the AMSYS Fusion Core Perception Platform, these solutions are designed to translate anonymous movement and occupancy data into actionable operational insights.

In a stadium or major event venue, for example, this approach could help operators monitor crowd density, analyze queues, and identify congestion across entrances and gathering areas. These insights could support better decisions about staffing, crowd movement, and resource allocation while maintaining a privacy-conscious approach to sensing.

Together, these collaborations demonstrate Seyond’s expanding role in connecting advanced sensing with AI, computing, and operational software. As investment in intelligent infrastructure grows, Seyond remains focused on bringing practical spatial intelligence solutions to cities, critical infrastructure and safe spaces.

About Seyond

Seyond is a global provider of high-performance LiDAR solutions for automotive, robotics, intelligent transportation, smart infrastructure, and other applications. Its comprehensive portfolio of advanced 3D sensing technologies enables accurate, reliable spatial intelligence across a wide range of environments.

For more information, visit www.seyond.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c501796e-599d-478e-86ec-4c3044e91d56

CONTACT: Seyond Media contact:

pr@seyond.com

VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — North Sky Metals Corp. (TSXV:NSKY) (“North Sky” or the “Company“) is pleased to report the completion of its 2026 diamond drill program at the Natlan Project (“Natlan” or the “Project“), located approximately 24 km northeast of New Hazelton in west-central British Columbia (Figure 1). The Company completed 12 diamond drill holes totalling 4,372 metres to test two targets: the Ace porphyry copper-molybdenum target with associated gold and silver, which had not been previously drill tested, and the West gold target.

The 2026 program marks an important step for North Sky as Natlan advances from surface exploration to drilling. Three years of systematic mapping, sampling and geophysics have established three drill-ready targets across the 100 km² property. The first two targets have now been tested, and the third, the East copper-molybdenum-gold-silver porphyry target, is fully permitted for its first drill test planned in 2027.

Highlights

  • Drilling program completed: 12 diamond drill holes totalling 4,372 metres were completed using a single helicopter-supported core rig;
  • First-ever drilling at Ace: six holes totalling 2,507 metres tested the approximately 1.75 km by 0.9 km copper-molybdenum soil geochemical anomaly. The anomaly at Ace has associated silver and gold values, coincident induced polarization (“IP”) chargeability highs, a ring-shaped magnetic high and mapped potassic and phyllic alteration;
  • Drilling at West: six holes totalling 1,865 metres followed up on limited historical drilling and tested approximately 350 metres of the approximately 900-metre-long by 550-metre-wide gold-arsenic soil anomaly with coincident chargeability and resistivity anomalies;
  • East target ready for drilling: the undrilled East target is an approximately 2.5 km long copper-molybdenum-gold-silver trend with an associated tungsten geochemical anomaly along the eastern margin of the Natlan stock, plus coincident IP chargeability and resistivity anomalies. The East target is permitted for a first drill test planned for summer 2027;
  • Drill core samples at the laboratory: 2,286 half-core samples and 384 samples for quality assurance/quality control (QA/QC) have been delivered to ALS for gold fire assay and multi-element analysis; and
  • Fully permitted for further exploration: multi-year area-based (MYAB) permits cover follow-up drilling at Natlan to March 2031 and at Ace to March 2030.

“Completion of drilling at Natlan is a milestone for North Sky following three years of mapping, sampling and geophysics that went into development of the drill targets at Ace and West,” said Scott Ansell, President and CEO of North Sky. “With multi-year exploration permits in place across the Project, we can move directly from results to follow-up drilling, and planning for 2027 is already underway.”

“The assay results will help us assess the mineralization encountered and prioritize opportunities for follow-up drilling. While assays are pending, we are integrating geological logging and geophysical data into 3D models of both targets, to provide a basis for a focused 2027 drill program,” commented Arron Albano, Exploration Manager of North Sky.

Figure 1 - NSKY Nov 3, 2026 NR

Figure 1. Location of the Natlan Project, west-central British Columbia.

2026 Drill Program

Drilling was carried out by Driftwood Diamond Drilling and started at the lower-elevation West target before moving to the higher-elevation Ace target (Figures 2 and 4). North Sky developed the program based on the 2024 airborne magnetic survey and approximately 24 line-km of IP surveying completed in 2023 and 2025, together with soil and rock geochemistry and geological mapping. Drill hole details are provided in Table 1.

Table 1. 2026 Natlan diamond drill hole details (UTM NAD83 Zone 9N)

Hole ID Target Easting Northing Elev. (m) Azimuth (°) Dip (°) Length (m)
NAT26DD001 West 603854 6142741 978 290 -50 304
NAT26DD002 West 603919 6142828 999 290 -50 324
NAT26DD003 West 603919 6142828 999 290 -65 335
NAT26DD004 West 603636 6142866 923 110 -50 373
NAT26DD005 West 603926 6142994 975 290 -50 307
NAT26DD006 West 603779 6142645 972 290 -50 222
NAT26DD007 Ace 606728 6139086 1690 295 -60 507
NAT26DD008 Ace 607160 6139027 1517 295 -60 452
NAT26DD009 Ace 607284 6139285 1373 295 -60 396
NAT26DD010 Ace 606925 6139226 1557 295 -75 402
NAT26DD011 Ace 606940 6139002 1637 295 -65 408
NAT26DD012 Ace 606728 6139086 1690 290 -85 342
Total 12 holes           4,372

Figure 2 - NSKY Nov 3, 2026 NR

Figure 2. Natlan Project (A) copper and (B) molybdenum soil geochemistry, with target areas and 2026 drilling.

Ace Target

The Ace target is a calc-alkaline porphyry copper-molybdenum target with associated gold and silver, defined by a prominent gossan over a northeast-trending swarm of Bulkley-age granitic dykes and a related granitic plug, with mapped potassic and phyllic alteration, chalcopyrite and molybdenite mineralization in a quartz stockwork, and an approximately 1.75 km by 0.9 km copper-molybdenum soil anomaly. High-grade grab samples of mineralized quartz veins and altered rocks have returned up to 2.12% copper and 0.83% molybdenum, and polymetallic veins cutting the intrusive rocks have returned up to 13.3 g/t gold and 1,800 g/t silver. Strong IP chargeability highs coincide with the stockwork and alteration zones, and airborne magnetics show a ring-shaped magnetic high over the dykes flanked by magnetic lows that follow the mapped alteration. Six holes were drilled from five pads across an area of approximately 550 m by 300 m, mostly oriented to the northwest across the dyke swarm, including two holes from a single pad to test the target at depth (Figure 3).

Figure 3 - NSKY Nov 3, 2026 NR

Figure 3. Ace target plan map showing 2026 drill holes, with copper and molybdenum soil contours, copper-in-rock samples, IP chargeability greater than 30 mV/V and magnetic features.

Figure 4 - NSKY Nov 3, 2026 NR

Figure 4. Natlan Project gold soil geochemistry, with target areas and 2026 drilling.

West Target

The West target is an approximately 900 m long by 550 m wide gold-arsenic soil geochemical anomaly, set within a broader north-northeast-trending arsenic anomaly, in an area largely covered by overburden and mature trees. Historical drilling in 2005 tested the target with two holes from a single pad.

In 2022, four of fourteen grab samples of quartz-arsenopyrite veins and altered feldspar porphyry float collected along an old logging road returned gold grades of 10.7, 5.26, 3.38 and 2.95 g/t, and follow-up sampling of similar quartz-arsenopyrite vein float in 2024 and 2025 returned up to 1.72 g/t gold.

IP surveys conducted by North Sky outlined chargeability highs and resistivity lows over the West target soil anomaly, which are strongest upslope to the east of the 2005 drilling. Airborne magnetics show a north-trending magnetic low that may mark a controlling structure. Six holes from five pads were drilled upslope and along strike from the 2005 pad, testing approximately 350 m of the anomaly (Figure 5).

Figure 5 - NSKY Nov 3, 2026 NR

Figure 5. West target plan map showing 2026 and 2005 drill holes, gold-in-soil and contoured arsenic-in-soil geochemistry.

East Target (Undrilled)

The East target is an approximately 2.5 km long copper-molybdenum-gold-silver trend along the eastern margin of the Natlan stock, where a gossan with phyllic and potassic alteration follows the contact with hornfelsed sedimentary rocks. A 500 m by 750 m core of chalcopyrite-molybdenite-pyrite quartz stockwork lies within a 700 m by 1,500 m copper-molybdenum-gold-silver talus fines anomaly, and high-grade grab samples have returned up to 3.0% copper, 1.25% molybdenum, 21.9 g/t gold and 224 g/t silver. A tungsten geochemical anomaly further sets the East target apart: 33 of approximately 64 rock samples from the target and its southeastern extension contain more than 0.01% W (100 ppm), up to 0.134% W (1,340 ppm), and tungsten in talus fines reaches up to 0.052% W (520 ppm).

The strongest resistivity anomaly and a strong chargeability anomaly over the East target coincide with the best exposed mineralization and the geophysical anomalies are interpreted to extend to more than 300 m depth, while a strong magnetic low flanks the eastern margin of the stock, where the contact corresponds to the strongest geochemistry over an approximately 2 km trend. The Company plans to complete the first drill test of the East target in summer 2027 and permits for drilling are already in place.

Next Steps

The 2026 program of drilling, core logging and sampling is complete. Assay results will be reported in upcoming news releases. Results will be integrated with geological logging and the geophysical and surface geochemical datasets to prioritize follow-up drilling at Ace and West.

North Sky has also completed a helicopter-borne MobileMT electromagnetic and magnetic survey over the entire Natlan Project, flown by Expert Geophysics Surveys Inc., on east-west lines spaced 200 m apart. Interpretation of the final survey data is underway, and the results will be reported at a later date.

Exploration Permitting

North Sky holds multi-year area-based (MYAB) Mines Act permits covering the Project, one for the Natlan claims (valid to March 2031) and one for the Ace claims (valid to March 2030), which together authorize up to 100 helicopter-supported drill sites and 115 line-km of IP surveys across the Ace, West and East targets.

First Nations

The Natlan Project lies within the traditional territory of the Gitxsan Nation, on the lax yip (territories) of the Hereditary Chiefs Luutkudziiwus and Yagosip. North Sky’s engagement with the Chiefs is ongoing and hands-on. It includes regular meetings, information sharing and updates on the Company’s activities, as well as helicopter visits to the Project so the Chiefs can see the work firsthand and return to areas of their territories where their families have lived, harvested and kept their adaawk (oral histories) for generations. The Chiefs are compensated for their time, which supports the feast system that underpins Gitxsan governance and benefits the wider Gitxsan community.

These visits also give the Company a direct view of the Chiefs’ priorities for the land. Foremost among them are water and fish habitat.

North Sky regards consultation as a long-term relationship and not a one-time permitting step, and incorporates the Chiefs’ knowledge of the land into how and where it works. The 2026 program was also supported by local and regional businesses, including Raven 37 for field labour and Skookum Daxgyet Services for drill pad construction.

QA/QC and Sampling Protocol

All drill core was logged, photographed and sampled on site by Company personnel. Sample intervals were generally 1 to 2 metres at the West target and 3 metres at the Ace target. Core was cut in half with a diamond saw, with one half sent for analysis and the other retained for reference. A total of 2,286 core samples representing 4,165 metres of core were submitted, together with 384 QA/QC samples comprising certified reference materials, blanks, and field duplicates.

Company personnel delivered samples to the ALS Canada Ltd. preparation facility in Terrace, British Columbia, where samples are crushed to 70% passing 2 mm and a 250 g split is pulverized to 85% passing 75 microns. Pulps are analyzed at ALS in North Vancouver for gold by 30 g fire assay with an ICP-AES finish (Au-ICP21), and by multi-element analysis (48 elements) using a four-acid digestion with an ICP-MS finish (ME-MS61). Over-limit copper and other elements are re-analyzed by four-acid ore-grade methods (Cu-OG62, ME-OG62). ALS is independent of the Company.

About the Natlan Project

The 10,065 hectare Natlan Project consists of 14 contiguous mineral tenures in the Omineca Mining Division, approximately 24 km northeast of New Hazelton and within 23 km of the provincial power grid and 18 km of the CN rail line. North Sky owns 100% of the Ace claims and holds an option to earn a 100% interest in the Natlan claims. The Project lies near the southeastern margin of the Bowser Basin, close to the Skeena Arch, and is underlain by Bowser Lake Group sedimentary rocks intruded by the Late Cretaceous Natlan stock and related dyke swarms of the Bulkley plutonic suite, which is associated with porphyry deposits in the region, including the past-producing Huckleberry mine. The Qualified Person has not verified the information regarding the Huckleberry mine or other regional deposits, and mineralization at those deposits is not necessarily indicative of mineralization on the Natlan Project.

The Project has been explored intermittently since 1967. More than 3,500 soil samples, including B- and C-horizon soils, talus fines and Ah (humus) soils, and more than 800 rock samples have been collected across the Project, including 1,675 soil and 298 rock samples collected by North Sky in 2023 and 2024. North Sky has also completed a 360 line-km airborne magnetic survey and approximately 24 line-km of IP surveying. Further information on the Project is available in the NI 43-101 technical report titled “NI 43-101 Technical Report on the Natlan Project in west-central British Columbia, Canada” by Jean Pautler, P.Geo., with an effective date of June 30, 2026, available on the Company’s profile on SEDAR+ (www.sedarplus.ca) and on the Company’s website at www.northskymetals.com.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Arron Albano, B.Sc., P.Geo., Exploration Manager for North Sky Metals Corp., who is a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Albano has verified the data disclosed in this news release, including sampling and analytical data, by reviewing the Company’s databases, analytical certificates and the technical report.

ABOUT NORTH SKY METALS CORP.

North Sky Metals Corp. is a Canadian mineral exploration company focused on copper and gold projects in Canada. The Company’s flagship 100 km² Natlan Project in west-central British Columbia, comprising the 100%-owned Ace claims and the Natlan claims under option to earn a 100% interest, hosts the Ace and East copper porphyry targets and the West gold target, all fully permitted for drilling. The Company also holds the 110 km² Jet copper project in Nunavut. North Sky is focused on advancing these and other projects through disciplined, discovery-driven exploration.

ON BEHALF OF THE BOARD OF DIRECTORS OF NORTH SKY METALS CORP.

Scott Ansell,
President, CEO & Director

FOR FURTHER INFORMATION, PLEASE CONTACT:

Scott Ansell
(T): +1 (604) 536-2711
(E): info@northskymetals.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Disclaimer for Forward-Looking Information

Certain information and statements in this news release may be considered forward-looking information or forward-looking statements for purposes of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative and grammatical variations) of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, without limitation, statements relating to the timing of receipt and release of assay results from the 2026 drill program; the interpretation of drilling, geological, geochemical and geophysical results, including the 3D modelling of the Ace and West targets; the interpretation and reporting of the results of the MobileMT electromagnetic and magnetic survey; the Company’s plans for follow-up drilling at the Ace and West targets, including a 2027 drill program, and a first drill test of the East target in summer 2027; the use and continued validity of the Company’s multi-year area-based permits; the Company’s ability to earn a 100% interest in the Natlan claims under its option agreement; the Company’s ongoing engagement with the Gitxsan Hereditary Chiefs; and the Company’s stated plans and schedules for the Natlan Project.

Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management’s current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. Material expectations, estimates and assumptions pertaining to forward-looking statements include, but are not limited to: the receipt of assay results within expected timeframes; the reliability of the Company’s sampling, QA/QC and analytical procedures; the accuracy of geological, geochemical and geophysical interpretations; the continued validity of, and the Company’s compliance with, its permits; the Company’s ability to make the payments and incur the expenditures required to exercise its option on the Natlan claims; the availability of drilling contractors, helicopter support, equipment and personnel on reasonable terms; favourable weather and access conditions; continued constructive relationships with the Gitxsan Hereditary Chiefs and local communities; the strength of precious and base metals prices; and the availability of additional capital on acceptable terms to fund the Company’s planned exploration. A number of risks and uncertainties could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including, but not limited to: delays in receiving or interpreting assay results; assay results that do not meet expectations or do not confirm the presence of economic mineralization; the uncertainty of geophysical and geochemical interpretations; delays or cost overruns in exploration programs; weather, access and seasonal constraints; unavailability of contractors, helicopters or equipment; failure to satisfy the terms of the option agreement for the Natlan claims; changes in permitting requirements or the suspension, cancellation or non-renewal of permits; Indigenous rights and title claims and the outcome of consultation; global economic conditions; precious and base metal price fluctuations; government regulation and policy risks; public involvement in the permitting process; environmental regulatory requirements and risks; the market price of the Company’s shares; the Company’s additional capital requirements and the availability of financing; competition for properties and experienced employees; possible loss of interests in exploration and development properties; inherent danger in mining and mineral exploration; the nature of exploration and development projects; political risk; currency fluctuations; the Company has no history of mining operations; property title rights; dependence on key personnel and qualified and experienced employees; insurance coverage; dilution from further equity financing and outstanding stock options and share purchase warrants; litigation and other legal proceedings; and conflicts of interest.

Undue reliance should not be placed on forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are in many cases beyond the Company’s control. Forward-looking statements are not guarantees of future performance, and the Company’s actual results may differ materially from statements made in this news release. The forward-looking statements in this news release are made as of the date hereof, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b07422c-ceb4-4a94-ba22-bc873e4b59a8

https://www.globenewswire.com/NewsRoom/AttachmentNg/e388e6b0-73d7-4c8a-ae5d-2a1d3d14102b

https://www.globenewswire.com/NewsRoom/AttachmentNg/17ee2572-6706-45b4-b48e-0958334bfcbc

https://www.globenewswire.com/NewsRoom/AttachmentNg/ab972e24-20ed-495c-bbdd-e246ccdcdf90

https://www.globenewswire.com/NewsRoom/AttachmentNg/348b2db5-a3df-4c94-a1f4-678dbdc55f00

Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy and operational execution appointed to lead company into new phase of clinical development and growth

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (Nasdaq: AVXL) (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for central nervous system diseases with significant unmet medical needs, today announced that on November 1, 2026, its Board of Directors appointed Terrie Kellmeyer, Ph.D., who had been serving as the Company’s Interim Chief Executive Officer, as the Company’s President and Chief Executive Officer. She will also join Anavex’s Board of Directors.

“Dr. Kellmeyer has provided steady leadership and a clear vision during an important period for Anavex, sharpening the focus of our clinical programs and advancing our engagement with the FDA,” said Peter Donhauser, D.O., member of the Board of Directors. “She brings a deep understanding of our science, a disciplined approach to execution and an unwavering commitment to patients. The Board’s decision reflects our unequivocal support for her strategy and her plans to build a top-notch management team, and we are confident she is the ideal leader to drive Anavex to its full potential.”

“I am honored by the Board’s confidence and grateful to our team, whose dedication over the past several months has positioned Anavex for its next chapter,” said Dr. Kellmeyer. “We have strengthened our operations, advanced each of our programs and established a constructive dialogue with the FDA. My priorities are clear: disciplined execution of our clinical plans, generating high-quality data to support regulatory decisions and transparent communication with patients, investors and regulators. We are accountable to the patients and families we serve and to our shareholders, and we intend to deliver on our commitments.”

Anavex is developing blarcamesine (ANAVEX®2-73) in Alzheimer’s disease, Rett syndrome and Fragile X syndrome. Under Dr. Kellmeyer’s interim leadership, the Company has achieved and recently announced several key milestones across its development portfolio, including the completion of key clinical pharmacology studies, U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application in Fragile X syndrome, and continued progress supporting its planned Phase 3 Rett syndrome program. Anavex’s strategy is centered on close collaboration with the FDA and advancing blarcamesine through well-designed clinical studies. With active INDs across each of its core indications, Anavex remains focused on generating clinical evidence, advancing its precision medicine approach and pursuing potential new treatment options for patients and families.

Dr. Kellmeyer brings more than 30 years of biopharmaceutical industry experience spanning clinical development, regulatory affairs, clinical operations and medical affairs. Prior to her appointment as Chief Executive Officer, she served as Interim Chief Executive Officer and Senior Vice President, Clinical Development at Anavex. Before joining Anavex, Dr. Kellmeyer held senior leadership positions at Aardvark Therapeutics, Acer Therapeutics, Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Amylin Pharmaceuticals and Gen-Probe, and played a key role in the advancement of multiple development programs and the achievement of significant regulatory milestones in the United States and Europe. Dr. Kellmeyer received her Ph.D. in Molecular Biology from SUNY Syracuse and completed a postdoctoral fellowship at the University of Rochester.

About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of central nervous system diseases with high unmet medical need. Further information is available at www.anavex.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the Company’s clinical trial plans, preclinical and clinical data, clinical development programs and business prospects, the Company’s leadership strategy and management team development, the execution and advancement of its clinical development plans, its planned Phase 3 Rett syndrome program, its collaboration and interactions with the FDA, the advancement of blarcamesine, the generation of additional clinical evidence, and the pursuit of potential new treatment options are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including volatility in the Company’s stock price and the market in general; the Company’s ability to raise additional capital; challenges seeking, and ultimately obtaining, regulatory approval for the Company’s product candidates; the ability of Fast Track designation or Breakthrough Therapy designation to lead to a faster FDA review and approval process; the Company’s ability to maintain any benefits associated with Orphan Drug Designation, including market exclusivity; undesirable side effects caused by the Company’s product candidates; the Company’s ability to attract and retain highly qualified personnel; the Company’s reliance on third parties; the Company’s ability to obtain and maintain sufficient intellectual property protection for our product candidates; the Company’s ability to defend against claims of intellectual property infringement; the Company’s ability to compete in the highly competitive biotechnology and pharmaceutical industries; and the other risks and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the Securities and Exchange Commission (“SEC”) on November 25, 2025, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2025, filed with the SEC on February 9, 2026, the Company’s Form 10-K/A for the fiscal year ended September 30, 2025, filed with the SEC on August 28, 2026, the Company’s Form 10-Q/A for the quarterly period ended December 31, 2025, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026, filed with the SEC on August 28, 2026, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the SEC on August 28, 2026, and subsequent filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof except as required by law.

Investor Relations:

SCR Partners, LLC
Alex Arzeno
Tel: 203-550-3972
Email: alex@scr-ir.com

Tripp Sullivan
Tel: 615-942-7077
Email: tsullivan@scr-ir.com

Media:

Sam Brown, LLC
Christy Curran
Tel: 615-414-8668
Email: christycurran@sambrown.com

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1×1 investor meetings at the UBS Global Biopharma Conference on November 16-17, 2026.

Details of the presentation can be found below.

Format: Fireside Chat
Presenter: Mani Mohindru, PhD (President and CEO)
Date: November 16, 2026
Time: 2:40 PM GMT

Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Cardiff’s lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated mCRC, addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single-agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact: 
Candice Masse 
Astr Partners 
candice.masse@astrpartners.com 

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management is scheduled to participate in three upcoming investor conferences:

Canaccord Genuity 20th Annual MedTech, Diagnostics, Digital Health & Services Forum 
Participation: Fireside Chat and 1×1 investor meetings
Date/Time: Fireside Chat Wednesday, November 11, 2026, 10:00 AM ET

Jefferies Global Healthcare Conference in London
Participation: Fireside Chat and 1×1 investor meetings
Date/Time: Fireside Chat Tuesday, November 17, 2026, 8:30 AM ET

Piper Sandler 38th Annual Healthcare Conference
Participation: Presentation and 1×1 investor meetings
Date/Time: Presentation Wednesday, December 2, 2026, 8:00 AM ET

Webcast events can be accessed live through the Investors page at www.axogeninc.com. For those unable to listen to the live broadcast, the replay will be archived for 90 days and available on the Investors page at www.axogeninc.com.

About Axogen

Axogen (Nasdaq: AXGN) is focused on the science, development and commercialization of technologies for peripheral nerve repair. With a mission to make nerve repair the expected standard of care, Axogen advances the field through research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen’s product portfolio includes Avance® (acellular nerve allograft-arwx), Avance® Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, Avive+ Soft Tissue Matrix™, and NerveTape®.

Contact:
Axogen, Inc.
InvestorRelations@axogeninc.com

CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, November 12, 2026 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress.

Conference Call and Webcast Information:

  • Date: Thursday, November 12, 2026 at 4:30 PM ET
  • Participant Dial-in (US): 1-800-717-1738
  • Participant Dial-in (International): 1-646-307-1865
  • Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://ir.relmada.com/investors/events/.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com

Media Inquiries:
Corporate Communications
media@relmada.com

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027

U.S. Biologics License Application (BLA) Submission for Risto-cel in Sickle Cell Disease Expected as Early as Year-End 2026

Dosing in Phase 1/2 Trial of BEAM-304 in PKU Anticipated to Initiate in Early 2027

Initial BEAM-301 Phase 1/2 Data Presented at ESGCT Demonstrated Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa; Enrollment in 60 mg Cohort Underway

Ended Third Quarter 2026 with $1.0 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into Mid-2029

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.

“Our progress this quarter reflects the growing maturity and momentum of Beam’s platform, with predictable clinical translation across four distinct programs and multiple potentially transformative medicines advancing toward patients, bringing our vision for a new era of genetic medicine increasingly within reach,” said John Evans, chief executive officer of Beam Therapeutics. “We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027. Recently, initial BEAM-301 clinical trial data showed exciting early evidence of clinical activity and provided further clinical validation of our in vivo LNP platform. Together with the planned initiation of BEAM-304 dosing in early 2027, these milestones reinforce our confidence in a platform designed to translate predictably, carry knowledge forward from one program to the next, and progressively expand the number of patients who can benefit from base editing.”

Third Quarter 2026 and Recent Progress and Anticipated Milestones

Liver-targeted Genetic Diseases

BEAM-302: BEAM-302, Beam’s lead genetic disease program, is an investigational base editing therapy designed to be a differentiated, first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly corrects the root cause of the disease and has the potential to address both liver and lung manifestations.

  • In September, Beam presented updated clinical data from the Phase 1/2 trial of BEAM-302 at the European Respiratory Society (ERS) Congress 2026, reinforcing its potential as a one-time treatment for both the lung and liver manifestations of AATD. With up to 18 months of follow-up, the data demonstrated durable increases in total and functional AAT, decreased circulating neutrophil elastase activity, and reductions in mutant Z-AAT and toxic circulating Z-polymers following a single dose. Evidence of AAT production under normal physiological control further supports BEAM-302’s potential to restore the body’s natural protective response, with a safety profile consistent with lipid nanoparticle (LNP)-based therapies.
  • Enrollment and dosing continue in the global pivotal cohort of the ongoing Phase 1/2 trial, which is designed to support a potential accelerated approval path in the United States. The company expects to complete dosing in the pivotal cohort in the first half of 2027.

BEAM-304: BEAM-304 is an investigational base editing program designed to leverage Beam’s proprietary base editing technology and LNP delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance BEAM-304 using a platform approach to develop mutation-specific base editors for the majority of patients with PKU.

  • Beam nominated its third base editor within the BEAM-304 program targeting a third undisclosed PKU mutation. Now encompassing three different base editors for distinct mutations, the company believes the BEAM-304 program has the potential to address up to 50% of PKU patients in the U.S., with ongoing research effort to address additional pathogenic mutations.
  • Beam continues clinical start-up activities for the planned Phase 1/2 trial of BEAM-304. The trial will initially evaluate safety, tolerability and reduction of blood phenylalanine (Phe) levels in patients with the R408W mutation, with the goal of establishing clinical proof of concept for base editing in PKU. The trial is designed to subsequently evaluate base editors for additional mutations within a single clinical program. Beam expects to initiate dosing in the Phase 1/2 trial in early 2027.

BEAM-301: BEAM-301, an investigational base editing therapy, aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa).

  • In October, Beam presented initial clinical data from the ongoing Phase 1/2 trial of BEAM-301 at the European Society of Gene & Cell Therapy (ESGCT) Congress. Initial BEAM-301 clinical data demonstrated dose-dependent improvements in time to fasting hypoglycemia (TTH) across all patients, with two of three patients in the 40 mg cohort achieving the protocol-defined maximum controlled fasting duration of 15 hours, consistent with restored endogenous glucose production, and complete elimination of starch supplementation. BEAM-301 demonstrated an acceptable safety profile across both doses, consistent with the known risks associated with LNP-based therapies​.
  • Based on the safety and clinical findings observed to date, Beam is enrolling patients in a 60 mg cohort of the ongoing open-label Phase 1/2 dose-exploration study and plans to engage with the U.S. FDA regarding a potential path to approval.

Hematology

Risto-cel: Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potentially differentiated profile for the treatment of sickle cell disease (SCD). 

  • Beam expects to report updated clinical data by year-end 2026 and submit a U.S. biologics license application (BLA) for risto-cel as early as year-end 2026.

Next-generation Programs in Sickle Cell Disease and Hematology:

  • Beam continues to make significant investments in developing targeted LNPs to deliver gene editing to hematopoietic stem cells (HSCs). Targeted LNPs for HSC delivery have been identified and are in advanced lead optimization.

Corporate Updates

  • In September, Beam appointed Eric Foster as chief commercial officer to lead the company’s commercial organization and strategy as its hematology and genetic disease programs advance toward potential launches. Mr. Foster is a seasoned biopharmaceutical executive with more than 25 years of commercial leadership experience, including senior roles at Ardelyx, Horizon Therapeutics, and GSK.

Upcoming Events
Beam management will participate in fireside chats at the following upcoming investor events:

  • Guggenheim 3rd Annual Healthcare Innovation Conference in Boston:
    Tuesday, November 10, 2026, at 9:00 a.m. ET.
  • UBS Global Biopharma Conference in London:
    Tuesday, November 17, 2026, at 2:00 p.m. GMT.
  • Jefferies Global Healthcare Conference in London:
    Wednesday, November 18, 2026, at 1:00 p.m. GMT.
  • 9th Annual Evercore Healthcare Conference in Miami:
    Wednesday, December 2, 2026, at 8:20 a.m. ET.

The live webcasts will be available in the investor section of the company’s website at www.beamtx.com and will be archived for 60 days following each presentation.

Third Quarter 2026 Financial Results

  • Cash Position: Cash, cash equivalents and marketable securities were $1.0 billion as of September 30, 2026, compared to $1.2 billion as of December 31, 2025.
  • Research & Development (R&D) Expenses: R&D expenses were $110.1 million for the third quarter of 2026, compared to $109.8 million for the third quarter of 2025.
  • General & Administrative (G&A) Expenses: G&A expenses were $31.5 million for the third quarter of 2026, compared to $26.7 million for the third quarter of 2025.
  • Net Income (Loss): Net loss was $134.4 million, or $1.28 per share, for the third quarter of 2026, compared to net loss of $112.6 million, or $1.10 per share, for the third quarter of 2025.

Cash Runway

Beam expects that its cash, cash equivalents and marketable securities as of September 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, assuming satisfaction of the conditions applicable to those additional borrowings. This runway is expected to support the company through the potential launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU and GSDIa, and our next-generation programs, including our development of targeted LNPs for hematopoietic stem cell delivery; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304, including the anticipated timing of clinical trial initiation and expansion; our planned submission of a BLA for risto-cel; our expectations regarding the potential launch of risto-cel; the potential for an accelerated approval path for BEAM-302; our anticipated regulatory interactions and filings; our expectations regarding the funds that will be available to draw under our credit facility with Sixth Street; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; our intentions regarding management’s participation in future investor events; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that we may not achieve the funding milestones under our credit facility with Sixth Street; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Contacts: 
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com

Media:
Josie Butler
1AB
josie@1abmedia.com

Condensed Consolidated Balance Sheet Data (unaudited)  
(in thousands)  
             
    September 30,
2026
    December 31,
2025
 
Cash, cash equivalents, and marketable securities   $ 1,043,873     $ 1,245,210  
Total assets     1,269,072       1,481,177  
Total liabilities     316,398       242,819  
Total stockholders’ equity     952,674       1,238,358  

Condensed Consolidated Statement of Operations (unaudited)  
(in thousands, except share and per share data)  
                         
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
License and collaboration revenue   $ 307     $ 9,698     $ 32,535     $ 25,634  
Operating expenses:                        
Research and development     110,110       109,769       309,730       310,343  
General and administrative     31,519       26,740       97,895       81,539  
Total operating expenses     141,629       136,509       407,625       391,882  
Loss from operations     (141,322 )     (126,811 )     (375,090 )     (366,248 )
Other income (expense):                        
Change in fair value of derivative liabilities     4,700       (2,600 )     3,000       1,900  
Change in fair value of non-controlling equity investments     (1,021 )     4,937       (667 )     7,271  
Change in fair value of contingent consideration liabilities     (2,856 )     1,000       (2,547 )     945  
Gain on sale of equity method investment     —       —       455       —  
Interest and other income (expense), net     6,094       10,903       23,448       33,093  
Total other income (expense)     6,917       14,240       23,689       43,209  
Net loss   $ (134,405 )   $ (112,571 )   $ (351,401 )   $ (323,039 )
Unrealized gain (loss) on marketable securities     (1,245 )     780       (4,545 )     111  
Comprehensive loss   $ (135,650 )   $ (111,791 )   $ (355,946 )   $ (322,928 )
Net loss per common share, basic and diluted   $ (1.28 )   $ (1.10 )   $ (3.38 )   $ (3.31 )
Weighted-average common shares outstanding, basic and diluted     104,698,517       102,570,801       104,100,991       97,567,229  

  

  • Third-quarter 2026 Rezdiffra® (resmetirom) net sales of $431.3 million, representing year-over-year growth of 50%; achieved first quarter of profitability
  • Rezdiffra reaches a major milestone, achieving blockbuster status with year-to-date net sales of $1.1 billion
  • As of Sept. 30, 2026, more than 55,850 patients on Rezdiffra, nearly doubling from 3Q25, reflecting continued strong prescriber adoption and high patient demand
  • U.S. F2-F3 MASH market is accelerating, growing to more than 530,000 addressable patients through June 30, 2026, on track for more than 30% growth by YE26
  • Madrigal strengthens its leadership position in well-compensated MASH cirrhosis (F4c) with new MAESTRO-CSPH outcomes clinical trial; MAESTRO NASH OUTCOMES on track, data expected late 2027 
  • Reports cash, cash equivalents, restricted cash and marketable securities of $961.8 million as of Sept. 30, 2026
  • Appointed John C. Reed, M.D., Ph.D., to Board of Directors
  • Company to host conference call today, Nov. 3, 2026, at 8 a.m. EST

CONSHOHOCKEN, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2026 financial results and provides corporate updates.

Bill Sibold, Chief Executive Officer of Madrigal, stated: “Madrigal delivered another strong quarter, driven by continued Rezdiffra demand, deepening prescriber adoption and accelerating market growth. Rezdiffra surpassed $1 billion in year-to-date net sales, achieving blockbuster status less than three years after launch, and we are still early in a rapidly growing market. Our latest analysis shows the addressable U.S. F2-F3 market is on track to increase more than 30 percent by year-end 2026, reinforcing how quickly this category is developing and the significant runway ahead.”

Sibold continued: “Madrigal’s next major opportunity is in well-compensated cirrhosis, or F4c, an urgent unmet need for patients. Our objective in F4c is clear: be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy to patients with this advanced stage of MASH. MAESTRO-CSPH is our new, Phase 3, practice-shaping trial that we expect will extend our competitive advantage and strengthen our long-term leadership in this rapidly growing market.”

Third Quarter 2026 and Recent Corporate Updates

  • Strengthens leadership in well-compensated MASH cirrhosis (F4c) with new MAESTRO-CSPH Phase 3 outcomes trial
    • Madrigal plans to initiate MAESTRO-CSPH, a second Phase 3 event-driven outcomes trial that builds on its ongoing MAESTRO-NASH OUTCOMES study. The trial is expected to enroll more than 2,000 F4c patients, with a population significantly enriched for clinically significant portal hypertension (CSPH). It is designed to generate the broadest dataset in F4c and support validation of noninvasive biomarkers for Rezdiffra and future pipeline programs. Trial initiation is expected in the first half of 2027, subject to regulatory discussions.
  • Madrigal to have strong presence at upcoming AASLD Liver Meeting
    • Madrigal will have a significant presence at the upcoming American Association for the Study of Liver Diseases (AASLD) Liver Meeting taking place Nov. 5-9 in Denver, CO. Resmetirom will be featured in more abstracts than any other MASH therapy at the conference. Eighteen Madrigal abstracts have been accepted, including 13 abstracts based on real-world evidence where the largest data set spans nearly 12,000 patients, underscoring the breadth of Madrigal’s evidence-generation program for Rezdiffra and MASH.
  • Journal of Hepatology publication demonstrates Rezdiffra’s consistent efficacy across common MASH genetic risk variants
    • Secondary analysis of the Phase 3 MAESTRO-NASH trial demonstrated Rezdiffra improved histology and MRI-PDFF across common genetic variants associated with MASH progression including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7, reinforcing Rezdiffra as a foundational treatment.
  • Appointed John C. Reed, M.D., Ph.D., to Madrigal’s Board of Directors
    • In August, Dr. John Reed was appointed to Madrigal’s Board of Directors. Currently Dr. Reed serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson where he leads research and development across oncology, immunology and neuroscience. He previously held executive leadership positions at both Sanofi and Roche.

Third-Quarter 2026 Financial Results

  • Total Revenues: Third-quarter 2026 net revenues were $431.3 million, an increase of 50% compared to $287.3 million in the comparable prior year period, driven by increased demand for Rezdiffra in the U.S. in 2026.
  • Operating Expenses: Third-quarter 2026 operating expenses were $375.3 million, inclusive of $38.9 million in non-cash stock-based compensation expense, compared to $401.2 million, inclusive of $26.3 million in non-cash stock-based compensation expense, in the comparable prior year period.
    • Cost of Sales: Third-quarter 2026 cost of sales was $37.8 million compared to $18.1 million in the comparable prior year period. The increase in cost of sales was primarily driven by higher royalties payable to Roche as a result of increased net sales of Rezdiffra in 2026.
    • R&D Expenses: Third-quarter 2026 R&D expenses were $71.8 million compared to $174.0 million in the comparable prior year period, both inclusive of non-cash stock-based compensation. The decrease in R&D expenses was primarily due to the one-time, upfront business development expense of $117.3 million in the comparable prior year period.
    • SG&A Expenses: Third-quarter 2026 SG&A expenses were $265.7 million compared to $209.1 million in the comparable prior year period, both inclusive of non-cash stock-based compensation. The increase in SG&A expenses was primarily due to continued investment in commercial activities for Rezdiffra, including headcount for the endocrinology field force expansion that began in the fourth quarter of 2025, and marketing efforts, including a direct-to-consumer (DTC) campaign.
  • Net Income: Third-quarter 2026 net income was $55.4 million, or $1.90 per basic share and $1.83 per diluted share, compared to a net loss of $114.2 million, or $4.01 per basic and diluted share, in the comparable prior year period.
  • Cash, Cash Equivalents, Restricted Cash and Marketable Securities: As of Sept. 30, 2026, Madrigal had cash, cash equivalents, restricted cash, and marketable securities of $961.8 million compared to $988.6 million as of Dec. 31, 2025.

Conference Call and Webcast
At 8 a.m. EST today, Nov. 3, 2026, Madrigal will host a webcast to review its financial and operating results and provide a general business update. To access the webcast, please visit the investor relations section of the Madrigal website or click here to register. An archived webcast will be available on the Madrigal website following the event.

About MASH
Metabolic dysfunction-associated steatohepatitis (MASH) is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, the need for liver transplantation, and premature mortality. MASH is the leading cause of liver transplantation in women and the second leading cause of all liver transplantation in the U.S. It is the fastest-growing indication for liver transplantation in Europe.

Once patients progress to MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), the risk of adverse liver outcomes increases dramatically: these patients have a 10 to 17 times higher risk of liver-related mortality as compared to patients without fibrosis. Patients with MASH who progress to cirrhosis face a 42 times higher risk of liver-related mortality, underscoring the need to treat MASH before complications of cirrhosis develop. MASH is also an independent driver of cardiovascular disease, the leading cause of mortality for patients.

As disease awareness improves and disease prevalence increases, the number of diagnosed patients with F2 to F4c MASH is growing.

About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Forward Looking Statements
This press release includes “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements related to the expected growth of Rezdiffra, expected growth of the MASH market, Madrigal’s leadership position in the MASH sector, the potential benefit of resmetirom in patients with compensated MASH cirrhosis, the expected receipt of data from the MAESTRO-NASH OUTCOMES trial in late 2027, the expected initiation of the MAESTRO-CSPH trial in the first half of 2027, the potential impact of positive results from Madrigal’s outcomes trials, expectations regarding competitor trials and the potential benefit of Madrigal’s pipeline candidates in the treatment of MASH. Forward-looking statements are based on Madrigal’s beliefs and assumptions on information currently available to it and are subject to a number of risks and uncertainties including, but not limited to: the assumptions underlying the forward-looking statements; Madrigal’s ability to successfully commercialize Rezdiffra in the U.S. and Europe; conditions imposed by regulators relating to the scope and design of Madrigal’s clinical trials; risks related to obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; Madrigal’s history of operating losses and the possibility that it may never achieve or maintain consistent profitability; risks associated with meeting the objectives of Madrigal’s clinical trials, including, but not limited to the ability to achieve enrollment objectives concerning patient numbers (including an adequate safety database), outcomes objectives and/or timing objectives for Madrigal’s trials; any delays or failures in enrollment, and the occurrence of adverse safety events; risks related to the effects of Rezdiffra’s (resmetirom’s) mechanism of action or of any other product candidate; market demand for and acceptance of Rezdiffra; Madrigal’s ability to service indebtedness and otherwise comply with debt covenants; outcomes or trends from competitors; future topline data timing or results; Madrigal’s ability to prevent and/or mitigate cyber-attacks; Madrigal’s ability to protect its intellectual property rights; the uncertainties inherent in clinical testing; uncertainties concerning analyses or assessments outside of a controlled clinical trial; and changes in laws and regulations applicable to Madrigal’s business and its ability to comply with such laws and regulations. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by applicable law, Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal’s reports filed with the U.S. Securities and Exchange Commission (SEC) for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. Madrigal specifically discusses these risks and uncertainties in greater detail in the sections appearing in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2025, and as updated from time to time by Madrigal’s other filings with the SEC.

Madrigal may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Madrigal’s website in addition to following its press releases, filings with the SEC, public conference calls, and webcasts.

Madrigal Pharmaceuticals, Rezdiffra® and associated logos are trademarks of Madrigal Pharmaceuticals, Inc.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

(tables follow)

               
Madrigal Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share amounts)
(unaudited)
               
  Three Months Ended   Nine Months Ended
  September 30,   September 30,
  2026   2025   2026   2025
Revenues:              
Product revenue, net $ 431,268     $ 287,268     $ 1,106,857     $ 637,320  
Operating expenses:              
Cost of sales   37,815       18,122       104,669       31,700  
Research and development   71,755       174,004       271,625       272,257  
Selling, general and administrative   265,709       209,117       823,605       573,851  
Total operating expenses (1)   375,279       401,243       1,199,899       877,808  
Income (loss) from operations   55,989       (113,975 )     (93,042 )     (240,488 )
Interest income   8,239       10,308       23,586       27,905  
Interest expense   (8,069 )     (7,451 )     (23,828 )     (14,012 )
Loss on extinguishment of debt   –       (2,779 )     –       (2,779 )
Other expense, net   (717 )     (293 )     (3,604 )     (335 )
Net income (loss) $ 55,442     $ (114,190 )   $ (96,888 )   $ (229,709 )
               
Net income (loss) per common, Series A preferred and Series B preferred share:              
Net income (loss) per common, Series A preferred, and Series B preferred share – basic $ 1.90     $ (4.01 )   $ (3.32 )   $ (8.12 )
Net income (loss) per common, Series A preferred, and Series B preferred share – diluted $ 1.83     $ (4.01 )   $ (3.32 )   $ (8.12 )
Weighted average number of shares outstanding – basic (2)   29,247,673       28,508,089       29,142,570       28,276,865  
Weighted average number of shares outstanding – diluted (2)   30,313,137       28,508,089       29,142,570       28,276,865  
               
(1) Amounts include non-cash stock-based compensation expense as follows:
Cost of sales $ 138     $ –     $ 363     $ –  
Research and development   8,676       6,473       23,401       17,042  
Selling, general and administrative   30,133       19,779       84,572       55,300  
Total stock-based compensation $ 38,947     $ 26,252     $ 108,336     $ 72,342  
               
(2) Basic weighted average shares outstanding reflect the weighted-average impact of common stock, previously issued pre-funded warrants, previously issued Series A and Series B convertible preferred shares outstanding, and earned PSUs during the period. Diluted weighted average shares outstanding also include the weighted average incremental shares from dilutive stock-based awards and warrants, as applicable.
                               

Madrigal Pharmaceuticals, Inc.  
Condensed Consolidated Balance Sheets  
(in thousands)  
(unaudited)  
  September 30,
  December 31,
  2026
  2025
Cash, cash equivalents, restricted cash and marketable securities $ 961,771     $ 988,649  
Trade receivables, net   227,377       134,476  
Other current assets   197,961       122,645  
Other non-current assets   47,280       13,819  
Total assets $ 1,434,389     $ 1,259,589  
           
Liabilities and Equity          
Current liabilities $ 454,244     $ 310,288  
Long-term liabilities   353,204       346,612  
Stockholders’ equity   626,941       602,689  
Total liabilities and stockholders’ equity $ 1,434,389     $ 1,259,589  
           

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.